Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18482287 | 0.92 | AAK1 (0.56) | AAK1CTSDEPHX2ALDH1A1LMNA | |
| SCHEMBL25319741 | 0.86 | AAK1 (0.65) | AAK1ALDH1A1LMNAPTPN1ITGA4 | |
| SCHEMBL5981368 | 0.84 | AAK1 (0.51) | AAK1PTPN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18511387 | 0.83 | AAK1 (0.61) | AAK1CTSDPTPN1ITGA4ITGB7 | |
| SCHEMBL25318130 | 0.82 | AAK1 (0.60) | AAK1ALDH1A1ITGA4ITGB7 | |
| SCHEMBL3750184 | 0.81 | AAK1 (0.58) | AAK1CTSDALDH1A1PTPN1ITGA4 | |
| SCHEMBL3750181 | 0.81 | AAK1 (0.58) | AAK1CTSDALDH1A1PTPN1ITGA4 | |
| SCHEMBL21029344 | 0.81 | AAK1 (0.58) | AAK1CTSDPTPN1ITGA4ITGB7 | |
| SCHEMBL30397375 | 0.81 | AAK1 (0.58) | AAK1CTSDPTPN1ITGA4ITGB7 | |
| SCHEMBL28961254 | 0.81 | AAK1 (0.58) | AAK1CTSDPTPN1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115766-B2 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | SNCA, PARK7, SAMHD1 | AAK1 3662/4885CTSD 371/4885MTNR1B 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.